Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Auris – executive interview

Auris – executive interview

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase II) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase Ib). With AM-301, Auris is developing a nasal spray for protection against airborne pathogens and allergens.

In this video, Auris founder and chief executive officer Thomas Meyer provides an update on the company’s lead programs, AM-125 and AM-201, discussing recently received positive data and outlining key milestones for Q4 and 2021. Thomas also introduces the company’s new program, AM-301, and discusses the how the establishment of its new subsidiary, Altamira Medica, will support this ongoing development.

< Previous
Next >

You may also be interested in these:

Consumer

Unlocking London’s hidden tunnels: Investing in a major underground tourist attraction
sharesoc pic

Investment Companies

ShareSoc webinar – The Biotech Growth Trust

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free